Covid-19: Sputnik vaccine rockets, thanks to Lancet boost.
2021
Journals risk being used in place of regulators when they publish studies of novel vaccines that have not yet been authorised by a major regulator. Chris van Tulleken argues that peer review is inadequate to decide the risk-benefit ratio of new drugs
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
9
References
7
Citations
NaN
KQI